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Background:  Adverse outcomes are typically observed in African-Americans with coronary artery disease (CAD). While this is attributed, in part, 
due to a lack of accessibility to established therapies, the mechanisms underlying this discord remain to be elucidated. The rate of progression of 
coronary atherosclerosis in African-Americans has not been characterized.
Methods:  3479 patients with angiographic CAD underwent serial intravascular ultrasound imaging to evaluate changes in atheroma burden in 7 
clinical trials of anti-atherosclerotic therapies. African-American (n=170) and Caucasian (n=3309) patients were compared with regard to risk factor 
control and disease progression.
Results:  African-American patients were more likely to be female (52% vs. 28%, p=0.002), have a higher BMI (33±6 vs. 31±6 kg/m2, p=0.002), 
a history of hypertension (86% vs. 79%, p=0.028), diabetes mellitus (42% vs. 31%, p=0.002) and stroke (13% vs. 3%, p<0.001) compared with 
Caucasian patients. Despite a high use of medical therapies (95% statin, 89% aspirin, 79% fi -blocker, 52% ACE inhibitor), African-Americans 
demonstrated higher levels of LDL-C (93±29mg/dL vs. 87±27 mg/dL, p=0.006), CRP (2.9mg/L vs. 2.0 mg/L, p<0.001) and systolic blood pressure 
(133±15mmHg vs. 129±13 mmHg, p<0.001). While total atheroma volume was comparable between groups at baseline (189±82 mm3 vs. 
192±83 mm3, p=0.82), on serial evaluation a reduction in TAV was observed in Caucasians (-3.06±1.66 mm3, p=0.064), but not African-Americans 
(0.51±2.14 mm3, p=0.811). Propensity matching that accounted for differences in risk factor control revealed that progression of TAV continued to 
be greater in African-American patients (0.13±2.10 mm3 vs. -3.71±1.69 mm3, p=0.026).
Conclusions:  African-American patients with CAD achieve less optimal risk factor control and greater progression of coronary atherosclerosis. 
These findings support the need for more intensification of risk factor modification in African-American patients.
